Dealing with NSCLC EGFR mutation testing and treatment: A comprehensive review with an Italian real-world perspective.

Critical reviews in oncology/hematology 2021 Apr

filter terms:

Since their discovery, relevant efforts have been made to optimize the detection approaches to EGFR mutations as well as the clinical management of EGFR-mutated NSCLC. The recent shift from single gene testing to novel comprehensive detection platforms along with the development of new generation tyrosine kinase inhibitors, targeting both common and uncommon EGFR-mutations, is leading to a progressive increase in the number of patients who may benefit from targeted approaches, with subsequent impact on their long-term survival and quality of life. However, a prompt and adequate implementation of the most recent diagnostic and treatment advances in the routine practice often remains critical to be specifically addressed. In this review we provide a complete and updated overview of the different detection platforms and therapeutic options currently available for the clinical management of advanced EGFR-positive NSCLC, summarizing scientific evidence and describing molecular testing as well as treatment practice in the real-word scenario. Copyright © 2021 Elsevier B.V. All rights reserved.

Citation

Umberto Malapelle, Sara Pilotto, Francesco Passiglia, Francesco Pepe, Pasquale Pisapia, Luisella Righi, Angela Listì, Paolo Bironzo, Lorenzo Belluomini, Fabrizio Tabbò, Maria Lucia Reale, Gianluca Russo, Caterina De Luca, Silvia Novello, Giancarlo Troncone. Dealing with NSCLC EGFR mutation testing and treatment: A comprehensive review with an Italian real-world perspective. Critical reviews in oncology/hematology. 2021 Apr;160:103300